You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
绿叶制药(02186.HK)血脂康片(LY 02404)获中国临床许可
格隆汇 09-09 17:52

格隆汇9月9日丨绿叶制药(02186.HK)发布公告,天然调脂药物血脂康片(LY 02404)已获国家药品监督管理局(NMPA)许可于中国开展临床试验。 

LY 02404 为已上市血脂康片的生产工艺变更品种。通过改进生产工艺,可显著提高主要有效成分含量,同时提高患者服药依从性,能够更好满足临床需求。该药物由集团自主研发,拥有自主知识产权,已获得中国和中国香港专利授权。

血脂康为集团旗下专利药品,有胶囊和片剂两种剂型。是目前国内唯一有临床硬终点获益的天然调脂药物。目前血脂康胶囊已完成的美国FDA二期临床研究和中国冠心病二级预防研究(CCSPS)等大型临床循证医学研究均证实:血脂康能够抑制胆固醇合成,并显着降低冠心病患者总死亡率、冠心病死亡率以及心血管事件发生率,不良反应少。

基于明确的降脂疗效和安全性,血脂康胶囊已被《中国成人血脂异常防治指南( 2016年修订版 )》推荐为一线血脂管理药物,列入《国家基本药物目录( 2018年版 )》。同时,血脂康片和血脂康胶囊均被纳入2019年中国《国家基本医疗保险、工伤保险和生育保险药品目录》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account